{"task_id": "7af8d39d4887c9ca", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 426/464)", "text": "p. 195)\nLung cancer (p. 185)\nSmoking Cessation\n419\n\n--- Page 441 ---\nMultisystem Disorders\nSELECTED MULTISYSTEM DISORDERS\nINFECTIONS\n\u0003\nBACTERIAL\nendocarditis, TB, Whipple\u2019s\n\u0003\nVIRAL\nHIV, HBV, HCV, EBV, CMV\n\u0003\nFUNGAL\nhistoplasmosis, aspergillosis\n\u0003\nPARASITIC\nschistosomiasis\nMALIGNANCY\n\u0003\nSOLID\nmetastatic, paraneoplastic\n\u0003\nLYMPHOPROLIFERATIVE\nleukemia, lymphoma\nINFLAMMATORY\nvasculitis, rheumatoid arthritis,\nscleroderma, SLE, IBD\nIATROGENIC\ndrugs\nINFILTRATIVE\ncryoglobulinemia,\nhemochroma\ntosis, amyloidosis, sarcoidosis, porphyria\nENDOCRINE\ndiabetes, hyperthyroidism\nHEMOCHROMATOSIS\nINHERITANCE\nautosomal recessive. Among the\nNorth American population of European descent,\napproximately 10% are heterozygous and 0.3% are\nhomozygous for hemochromatosis\nPATHOPHYSIOLOGY\nmutation of HFE C282Y (nor\nmally forms a complex with transferrin receptor to\ndecrease its affinity for transferrin) ! \" absorption of\nFe ! iron deposition in organs\nCLINICAL\nFEATURES\nskin\n(bronze),\njoints\n(destructive arthritis, classically 2nd and 3rd MCP),\nheart (arrhythmia, heart failure), pancreas (\u2018\u2018bronze\u2019\u2019\ndiabetes), thyroid (hypothyroidism), liver (\" LFT,\ncirrhosis, hepatocellular carcinoma 200\u0002 \" risk, cho\nlangiocarcinoma\nrare),\ngonads\n(hypogonadism,\nimpotence), pituitary (hypopituitarism)\nDIAGNOSIS\ntransferrin % saturation (=serum iron/\nTIBC \u0002100%, \", most useful for screening), Fe (\"),\nTIBC, ferritin (\"), liver biopsy (hepatic iron index), HFE\ngenotype testing\nTREATMENTS\nalcohol\ncessation,\nphlebotomy\n(remove 1 2 U weekly until ferritin <50 ng/mL)\nNEJM 2004 350:23\nSARCOIDOSIS\nPATHOPHYSIOLOGY\ncause unknown but may\ninvolve antigen exposure ! activation of T cell\nimmunity ! non caseating granuloma formation\nCLINICAL\nFEATURES\nconstitutional\n(fatigue,\nweight loss, fever), pulmonary (staged according to\nCXR. Stage 0=no CXR changes, stage I=hilar adeno\npathy, stage II=hilar adenopathy with parenchymal\nopacities, stage III=parenchymal opacities without\nhilar adenopathy, stage IV=advanced fibrosis with\nevidence of honey combing, hilar retraction, bullae,\ncysts, and emphysema. Stages are not necessarily\nSARCOIDOSIS (CONT\u2019D)\nchronological), cardiac (arrhythmia especially con\nduction blocks, HF), GI tract (rarely ulcers, obstruc\ntion), renal (interstitial nephritis), neurologic (cranial\nnerve palsies especially CN VII, pituitary dysfunction,\nperipheral neuropathy, neuromuscular, transverse\nmyelitis), ocular (uveitis), endocrine (hypercalce\nmia), lymphatics (lymphadenopathy, hypersplen\nism), joints/bone (arthritis of knees, ankles, elbows,\nwrists, small joints of hands and feet, bone pain), and\nskin (erythema nodosum, lupus pernio). Lofgren\u2019s\nsyndrome is an acute presentation characterized by\nbilateral hilar lymphadenopathy, erythema nodosum,\narthritis, fever, \u0006uveitis (50%). It is associated with a\ngood prognosis with >80% remission in 2 years\nINVESTIGATIONS\nblood tests (CBCD, lytes, urea,\nCr, Ca, PO4, AST, ALT, ALP, bilirubin, serum ACE level),\nurine tests (urinalysis), imaging (CXR, CT chest),\nspecial (TB skin test, ECG, PFT, LP if neurological\nsymptoms, BAL, biopsy). Diagnosis is made by clinical\nfindings plus biopsy (except if Lofgren\u2019s syndrome)\nPROGNOSIS\npoor prognostic factors include age at\nonset >40, black race, progressive pulmonary sarcoi\ndosis, neurological or cardiac involvement, chronic\nuveitis, lupus pernio, chronic hypercalcemia, and\nnephrocalcinosis\nTREATMENTS\n\u0003\nLUNG INVOLVEMENT\nobservation only if asympto\nmatic, minimal parenchymal changes, Lofgren\u2019s\nsyndrome, or stage I lung disease as high chance\nof spontaneous remission. Inhaled steroids for mild\ndisease and systemic steroid (prednisone 1 mg/kg\nPO daily) for moderate/severe disease\n\u0003\nSKIN AND EYE INVOLVEMENT\ntopical steroid\n\u0003\nJOINT INVOLVEMENT\nNSAIDs/colchicine\n\u0003\nCARDIAC OR NEUROLOGIC INVOLVEMENT OR ANY OTHER\nPROGRESSIVE DISEASE\nprednisone 0.5 1 mg/kg PO\ndaily, methotrexate, azathioprine, cyclophospha\nmide and infliximab\nNEJM 2007 357:21\nAMYLOIDOSIS\nPATHOPHYSIOLOGY\nsoluble amyloid precursor\nprotein (AL=Ig light chain variable region in mye\nloma, AA=serum amyloid A in chronic inflammatory\nconditions, ATTR=derived from mutant transthyretin\nprotein, Ab=Ab protein precursor in Alzheimer\u2019s) !\ninsoluble fibrils in anti parallel b pleated sheet con\nfiguration ! deposition in different organs\nCLINICAL\nFEATURES\nconstitutional\n(fatigue,\nweight loss), renal (nephrotic range proteinuria, dis\ntal RTA, nephrogenic diabetes insipidus), cardiac (HF,\ncardiomyopathy,\narrhythmia,\nheart\nblock,\nMI),\n420\nMultisystem Disorders", "text_length": 4509, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 426/464)", "type": "chunk", "chunk_index": 425, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.834506", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.835450", "status": "pending"}